EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multifunctional Antidiabetic Effects of Myricetin via α-Glucosidase Inhibition and Enhanced Glucose Utilization

Ankita Arvind Yadav, Vaishnavi Rajendra Fugate, Pratiksha Jagtap

Journal of Integrative and Translational Biomedicine · 2026

DOI: 10.67316/jintb.v1.i3.31 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Integrative and Translational Biomedicine, 2026. Verfasst von Ankita Arvind Yadav und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus is also characterized by uncontrolled postprandial hyperglycemia, which is mediated by α-glucosidase activity. Current α-glucosidase inhibitors, e.g., acarbose, are limited by gastrointestinal side effects and localized intestinal action. Myricetin is a natural flavonoid with reported metabolic regulatory properties. This study explores the α-glucosidase inhibitory potential of myricetin and its potential in regulating diabetes-related biological pathways using integrated in silico and in vitro approaches.

Methods

Molecular docking was performed to evaluate the binding affinity and interaction of myricetin with α-glucosidase (PDB: 9GSW) in comparison with acarbose. In vitro α-glucosidase inhibitory activity was determined using a colorimetric assay, and inhibitory concentration (IC₅₀) values were calculated. Glucose uptake assay was performed in cells, and effective concentration (EC50) values were calculated. Target prediction followed by functional enrichment analysis was conducted to identify biological processes and signaling pathways regulated by myricetin.

Results

Myricetin exhibited stable binding with α-glucosidase (−7.5 kcal/mol), comparable to acarbose (−7.2 kcal/mol). In vitro assays showed concentration-dependent inhibition with an IC₅₀ of 69.42 ± 1.13 µg/mL, while acarbose showed stronger potency (IC₅₀ = 50.71 ± 0.78 µg/mL; p < 0.0001). The glucose uptake assay showed an EC50 of myricetin 59.88 ± 1.00 µg/mL vs metformin = 46.57 ± 2.41 µg/mL; p

Zitieren

APA

Yadav, A. A., Fugate, V. R., & Jagtap, P. (2026). Multifunctional Antidiabetic Effects of Myricetin via α-Glucosidase Inhibition and Enhanced Glucose Utilization. Journal of Integrative and Translational Biomedicine. https://doi.org/10.67316/jintb.v1.i3.31

Vancouver

Yadav AA, Fugate VR, Jagtap P. Multifunctional Antidiabetic Effects of Myricetin via α-Glucosidase Inhibition and Enhanced Glucose Utilization. Journal of Integrative and Translational Biomedicine. 2026. doi:10.67316/jintb.v1.i3.31

BibTeX
@article{Yadav2026,
  author = {Yadav, Ankita Arvind and Fugate, Vaishnavi Rajendra and Jagtap, Pratiksha},
  title = {Multifunctional Antidiabetic Effects of Myricetin via α-Glucosidase Inhibition and Enhanced Glucose Utilization},
  journal = {Journal of Integrative and Translational Biomedicine},
  year = {2026},
  doi = {10.67316/jintb.v1.i3.31}
}
Kostenlos starten →